▶Neonate 21 days to 28 days: 25 mg/kg every 6 – 8 hours.▶Child: 50 mg/kg every 8 – 12 hours
Severe susceptible infections due to sensitive Gram-
positive and Gram-negative bacteria|Meningitis
▶BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS
INJECTION, OR BY INTRAVENOUS INFUSION
▶Neonate up to 7 days: 50 mg/kg every 12 hours.▶Neonate 7 days to 20 days: 50 mg/kg every 8 hours.▶Neonate 21 days to 28 days: 50 mg/kg every 6 – 8 hours.▶Child: 50 mg/kg every 6 hours; maximum 12 g per day
Emergency treatment of suspected bacterial meningitis or
meningococcal disease, before urgent transfer to
hospital, in patients who cannot be given
benzylpenicillin (e.g. because of an allergy)
▶BY INTRAVENOUS INJECTION, OR BY INTRAMUSCULAR
INJECTION
▶Child 1 month–11 years: 50 mg/kg for 1 dose
▶Child 12–17 years: 1 gfor 1 doselINTERACTIONS→Appendix 1 : cephalosporins
lSIDE-EFFECTS
▶UncommonDrug fever.Jarisch-Herxheimer reaction.
renal impairment.seizure
▶Frequency not knownArrhythmia (following rapid
injection).bronchospasm.encephalopathy.
granulocytopenia.hepatic disorders
lPREGNANCYNot known to be harmful.
lBREAST FEEDINGPresent in milk in low concentration, but
appropriate to use.
lRENAL IMPAIRMENT
Dose adjustmentsUsual initial dose, then use half normal
dose if estimated glomerularfiltration rate less than
5 mL/minute/ 1. 73 m^2.
lDIRECTIONS FOR ADMINISTRATION
▶With intravenous useDisplacement value may be significant,
consult local guidelines. For intermittentintravenous
infusiondilute in glucose 5 %orsodium chloride 0. 9 %;
administer over 20 – 60 minutes; incompatible with
alkaline solutions.
lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.
Powder for solution for injection
▶Cefotaxime (Non-proprietary)
Cefotaxime (as Cefotaxime sodium) 500 mgCefotaxime 500 mg
powder for solution for injection vials| 10 vialP£ 21. 00 – £ 30. 00
Cefotaxime (as Cefotaxime sodium) 1 gramCefotaxime 1 g powder
for solution for injection vials| 10 vialP£ 35. 00 – £ 42. 00
Cefotaxime (as Cefotaxime sodium) 2 gramCefotaxime 2 g powder
for solution for injection vials| 10 vialP£ 37. 50
eiiiiF 317
Ceftazidime 02-Aug-2017
lINDICATIONS AND DOSE
Pseudomonal lung infection in cystic fibrosis
▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION,
OR BY DEEP INTRAMUSCULAR INJECTION
▶Child: 50 mg/kg every 8 hours; maximum 9 g per day
Febrile neutropenia
▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION
▶Child: 50 mg/kg every 8 hours; maximum 6 g per day
Meningitis
▶BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
▶Neonate up to 7 days: 50 mg/kg every 24 hours.▶Neonate 7 days to 20 days: 50 mg/kg every 12 hours.▶Neonate 21 days to 28 days: 50 mg/kg every 8 hours.▶Child: 50 mg/kg every 8 hours; maximum 6 g per day
Susceptible infections due to sensitive Gram-positive and
Gram-negative bacteria
▶BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
▶Neonate up to 7 days: 25 mg/kg every 24 hours.▶Neonate 7 days to 20 days: 25 mg/kg every 12 hours.▶Neonate 21 days to 28 days: 25 mg/kg every 8 hours.▶Child: 25 mg/kg every 8 hours; maximum 6 g per day
Severe susceptible infections due to sensitive Gram-
positive and Gram-negative bacteria
▶BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
▶Neonate up to 7 days: 50 mg/kg every 24 hours.▶Neonate 7 days to 20 days: 50 mg/kg every 12 hours.▶Neonate 21 days to 28 days: 50 mg/kg every 8 hours.▶Child: 50 mg/kg every 8 hours; maximum 6 g per day
ChronicBurkholderia cepaciainfection in cystic fibrosis
▶BY INHALATION OF NEBULISED SOLUTION
▶Child: 1 g twice dailylUNLICENSED USENebulised route unlicensed.
lINTERACTIONS→Appendix 1 : cephalosporins
lSIDE-EFFECTS
▶Common or very commonThrombocytosis
▶Rare or very rareAcute kidney injury
▶Frequency not knownComa.drug reaction with
eosinophilia and systemic symptoms (DRESS).
encephalopathy.jaundice.lymphocytosis.myoclonus.
neurological effects.paraesthesia.seizure.taste altered.
tremor
lPREGNANCYNot known to be harmful.
lBREAST FEEDINGPresent in milk in low concentration, but
appropriate to use.
lHEPATIC IMPAIRMENTManufacturer advises caution in
severe impairment.
lRENAL IMPAIRMENT
Dose adjustmentsManufacturer advises reduce dose if
creatinine clearance 50 mL/minute or less—consult
product literature.
lDIRECTIONS FOR ADMINISTRATIONIntramuscular
administration used when intravenous administration not
possible; single doses over 1 g by intravenous route only.
▶With intravenous useDisplacement value may be significant,
consult local guidelines. For intermittent intravenous
infusion dilute reconstituted solution further to a
concentration of not more than 40 mg/mL in Glucose 5 %
or Glucose 10 %orSodium chloride 0. 9 %; give over
20 – 30 minutes.
▶When used by inhalationFor nebulisation, dissolve dose in
3 mL of water for injection.lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug. Forms available from special-order
manufacturers include: infusion, solution for infusion
Powder for solution for injection
ELECTROLYTES:May contain Sodium
▶Ceftazidime (Non-proprietary)
Ceftazidime (as Ceftazidime pentahydrate) 500 mgCeftazidime
500 mg powder for solution for injection vials| 1 vialP£ 4. 25
Ceftazidime (as Ceftazidime pentahydrate) 1 gramCeftazidime 1 g
powder for solution for injection vials| 10 vialP£ 13. 90 – £ 79. 10BNFC 2018 – 2019 Bacterial infection 321
Infection5